Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 15/20 | 0.77 |
| ▸ | PDCD1 | Q15116 | 13/20 | 0.77 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19549760 | 0.93 | CD274 (0.71) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL19549692 | 0.89 | CD274 (0.82) | CD274PDCD1 | |
| SCHEMBL15933628 | 0.88 | CD274 (0.59) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL19549686 | 0.87 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL19549711 | 0.87 | CD274 (0.65) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL19549722 | 0.85 | PDCD1 (0.82) | CD274PDCD1 | |
| SCHEMBL19549793 | 0.85 | CD274 (1.00) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL19549685 | 0.81 | PDCD1 (0.65) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL19549679 | 0.79 | CD274 (0.62) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL19549737 | 0.79 | PDCD1 (1.00) | CD274PDCD1TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608337-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | claimed |
| EP-3452476-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-12-15 | — | — | EP | claimed |
| EP-3452476-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Holdings Corporation (US) | 2019-03-13 | — | — | EP | claimed |
| US-20190071439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-03-07 | — | — | US | claimed |
| WO-2017192961-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-09 | — | — | WO | claimed |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-09 | — | — | US | claimed |
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-11608337-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| US-20220168268-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2022-06-02 | — | — | US | disclosed |
| EP-3943083-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| EP-3452476-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20200172541-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| US-20190071439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-03-07 | — | — | US | disclosed |
| US-20190071439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-03-07 | — | — | US | disclosed |
| WO-2017192961-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-09 | — | — | US | disclosed |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-09 | — | — | US | disclosed |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885TLR9 112/4885 |
| US-20190071439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885TLR9 112/4885 |
| US-20220168268-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | PDCD1, PDCD1LG2, CD274 | CD274 3/4885PDCD1 1/4885TLR9 1832/4885 |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885TLR9 112/4885 |
| US-20200172541-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885TLR9 112/4885 |
| US-11608337-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885TLR9 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.